

Doc code :IDS

Doc description: Information Disclosure Statement (IDS) Filed

Approved for use through 04/30/2008. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>( Not for submission under 37 CFR 1.99)</i>	Application Number		10578470	
	Filing Date		2008-05-08	
	First Named Inventor		Jacques Bollekins	
	Art Unit			
	Examiner Name			
	Attorney Docket Number		33264-US-PCT	

U.S.PATENTS						
Examiner Initial*	Cite No	Patent Number	Kind Code <sup>1</sup>	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Patent citation information please click the Add button.

## U.S.PATENT APPLICATION PUBLICATIONS

Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Published Application citation information please click the Add button.

## FOREIGN PATENT DOCUMENTS

Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Country Code <sup>2</sup>	Kind Code <sup>4</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T <sup>5</sup>
	1	2002088358	WO	A2	2002-11-07	Geneprot		<input type="checkbox"/>
	2	2001066596	WO		2001-09-13	Chiron		<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button

## NON-PATENT LITERATURE DOCUMENTS

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /C.S./

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>( Not for submission under 37 CFR 1.99)</i>	Application Number	10578470
	Filing Date	2008-05-08
	First Named Inventor	Jacques Bollekens
	Art Unit	
	Examiner Name	
	Attorney Docket Number	33264-US-PCT

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	Ts
	1	International Search Report for related International Application PCT/EP2004/012572 mailed August 8, 2005.	<input type="checkbox"/>
	2	Database: Geneseq 'Online' 28 March 2003, "Human fibroblast growth factor 23 polypeptide.", XP002316719 retrieved from EBI accession no. GSN:ABP58110 Database Accession No. ABP58110 in it's entirety.	<input type="checkbox"/>
	3	Jonsson, K.B. et al., "Fibroblast Growth Factor 23 in Oncogenic Osteomalacia and X-Linked Hypophosphatemia", New England Journal of Medicine, 2003, Vol. 348, pp. 1656-63.	<input type="checkbox"/>
	4	Quarles, L. Darryl, "FGF23, PHEX, and MEPE regulation of phosphate homeostasis and skeletal mineralization", American Journal of Physiology Endocrinology and Metabolism, 2003, Vol. 285, pp. E1-E9.	<input type="checkbox"/>
	5	Bowe, Anne "FGF-23 Inhibits Renal Tubular Phosphate Transport and is a PHEX Substrate", Biochemical and Biophysical Research Communications, 2001, Vol. 284, pp. 977-981.	<input type="checkbox"/>
	6	Ornitz, David M. et al. "Fibroblast growth factors", Genome Biology, 2001, Vol. 2(3), pp. 3005.1-3005.12.	<input type="checkbox"/>
	7	Yamashita, T. et al., "Identification of a Novel Fibroblast Growth Factor, FGF-23, Preferentially Expressed in the Ventrolateral Thalamic Nucleus of the Brain", Biochemical and Biophysical Research Communications, 2000, Vol. 277, pp. 494-498.	<input type="checkbox"/>
	8	<del>www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10578470&amp;dopt=Abstract</del> not in compliance - no date	<input type="checkbox"/>
	9	<a href="http://ihg.gsf.de/ihg/patinfo/diagnostik/hyp.html">http://ihg.gsf.de/ihg/patinfo/diagnostik/hyp.html</a> : "Hypophosphatamie, X-chromosomal dominant", 2003.	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /C.S./

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number	10578470
Filing Date	2008-05-08
First Named Inventor	Jacques Bollekens
Art Unit	
Examiner Name	
Attorney Docket Number	33264-US-PCT

**EXAMINER SIGNATURE**

Examiner Signature	/Christine Saoud/	Date Considered	06/07/2010
--------------------	-------------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> See Kind Codes of USPTO Patent Documents at [www.USPTO.GOV](http://www.USPTO.GOV) or MPEP 901.04. <sup>2</sup> Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>3</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>4</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.18 if possible. <sup>5</sup> Applicant is to place a check mark here if English language translation is attached.